Emrelis Injection, Powder, Lyophilized, For Solution
Product Images NDC 0074-1044

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Emrelis (NDC 0074-1044). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Abbvie Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Telisotuzumab Vedotin-tllv Is A C-met Directed Antibody-drug Conjugate (adc) Comprised Of A Humanized Immunoglobulin G1 Kappa (igg1κ) Monoclonal Antibody Conjugated To The Small Molecule Microtubule-disrupting Agent, Monomethyl Auristatin E (mmae), Via A Protease-cleavable Valine-citrulline (vc) Linker. The Antibody Is Produced In A Mammalian Cell Line (chinese Hamster Ovary) And The Drug-linker Is Produced By Chemical Synthesis. Each Monoclonal Antibody Molecule Carries An Average Of 3 Mmae Molecules. Telisotuzumab Vedotin-tllv Has An Approximate Molecular Weight Of 152 Kda. (Emrelis Teliso V 01)

Telisotuzumab Vedotin-tllv Is A C-met Directed Antibody-drug Conjugate (adc) Comprised Of A Humanized Immunoglobulin G1 Kappa (igg1κ) Monoclonal Antibody Conjugated To The Small Molecule Microtubule-disrupting Agent, Monomethyl Auristatin E (mmae), Via A Protease-cleavable Valine-citrulline (vc) Linker. The Antibody Is Produced In A Mammalian Cell Line (chinese Hamster Ovary) And The Drug-linker Is Produced By Chemical Synthesis. Each Monoclonal Antibody Molecule Carries An Average Of 3 Mmae Molecules. Telisotuzumab Vedotin-tllv Has An Approximate Molecular Weight Of 152 Kda. (Emrelis Teliso V 01)
FDA Label Image

Principal Display Panelndc 0074-1044-01emrelis™(telisotuzumab Vedotin-tllv)for Injection20 mg Per Vialhazardous Drugfor Intravenous Infusion After Reconstitutionand Dilutionsingle-dose Vialdiscard Unused Portiondispense The Enclosed Medication Guide To Each Patientrx Onlyabbvie (Emrelis Teliso V 02)

Principal Display Panelndc 0074-1044-01emrelis™(telisotuzumab Vedotin-tllv)for Injection20 mg Per Vialhazardous Drugfor Intravenous Infusion After Reconstitutionand Dilutionsingle-dose Vialdiscard Unused Portiondispense The Enclosed Medication Guide To Each Patientrx Onlyabbvie (Emrelis Teliso V 02)
FDA Label Image

Principal Display Panelndc 0074-1055-01emrelis™(telisotuzumab Vedotin-tllv)for Injection100 mg Per Vialhazardous Drugfor Intravenous Infusion After Reconstitutionand Dilutionsingle-dose Vialdiscard Unused Portiondispense The Enclosed Medication Guide To Each Patientrx Onlyabbvie (Emrelis Teliso V 03)

Principal Display Panelndc 0074-1055-01emrelis™(telisotuzumab Vedotin-tllv)for Injection100 mg Per Vialhazardous Drugfor Intravenous Infusion After Reconstitutionand Dilutionsingle-dose Vialdiscard Unused Portiondispense The Enclosed Medication Guide To Each Patientrx Onlyabbvie (Emrelis Teliso V 03)